Kanika Monga, MD DrKanikaMonga
6 years 11 months ago
“Health tech isn’t just the future, it is the present” - @gnayyar
Listen to the incredible Dr. Geeta Nayyar talk to us about health tech, and about her favorite sessions at #ACR19!
@RheumNow https://t.co/OcYBws7pFE
Jonathan Hausmann MD hausmannMD
6 years 11 months ago
CAPS (cryopyrin-associated periodic syndrome) is a heterogeneous group of autoinflammatory conditions that causes intermittent fevers (typically after cold exposure), as well as an urticarial-like rash. #ACR19 @RheumNow
Janet Pope Janetbirdope
6 years 11 months ago
Remission ever or sustained in RA is same on triple DMARDs Therapy bs biological Rx. From Swedish register. ?channeling bias ?differential access? Either way this supports triple therapy use as impt in RA #ACR #ACR19 @RheumNow Abstract 2908 https://t.co/T8fRPr5a2A
Jonathan Hausmann MD hausmannMD
6 years 11 months ago
Haploinsufficiency 20 (HA20) is a newly-described autoinflammatory disease caused by mutations in TNFAIP3, encoding the NF-kB regulatory protein A20.
#ACR19 @RheumNow
Janet Pope Janetbirdope
6 years 11 months ago
Gout guidelines Allopurinol over febuxostat, dose low &slowly increase, T2T for serum Uric acid. Only Febuxostat if allopurinol failure/hypersensitivity. Only if failing with flares &tophi use peguricase. flares: colchicine steroids or NSAIDs #ACR @RheumNow https://t.co/ec6bOs5Hxo
Gout Study Group GoutGroup
6 years 11 months ago
2020 DRAFT ACR #gout Clinical Guidelines strongly recommend setting a serum urate goal and an active strategy to reach that goal @RheumNow https://t.co/8A6iTJgRPJ
Myosin Regulation May Contribute to Anti-TNF Therapy Response: Dr. Elaine Husni
Dr. Husni highlights abstract #1769 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Inflammatory Arthritis Persists After Immunotherapy Cessation: Dr. David Liew
Dr. Liew discusses abstract #1808 Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis Persists After Immunotherapy Cessation presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Studies on the Changing Face of RA: Dr. Janet Pope
Dr. Pope discusses abstract #171, #172 and #841 as presented at the 2019 ACR/ARP Annual Meeting in Atlanta.
Panel Presentation: Rheumatoid Arthritis
Drs. Jack Cush, Arthur Kavanaugh and Jonathan Kay discuss several rheumatoid arthritis studies presented at the 2019 ACR/ARP Annual Meeting in Atlanta. Abstracts discussed include abstract #1342, #1350, #1160, and more.
Drug Levels Associated with Lupus Flares: Dr. Janet Pope:
Dr. Pope discusses abstract #2567 Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates presented at the 2019 ACR/ARP annual meeting in Atlanta.
Safety of Methotrexate (The CIRT Trial): Dr. Jack Cush
Dr. Cush discusses abstract #1890 on the CIRT trial as presented at the 2019 ACR/ARP annual meeting in Atlanta.
Dr. Rachel Tate uptoTate
6 years 11 months ago
Tildrakizumab (TIL), anti–IL-23p19 monoclonal ab, superior to PBO in phase 2b trial results in PsA. https://t.co/i0vIEHD4hx #ACR19 @RheumNow abs#2878 https://t.co/OmlhZfGdJi
Jonathan Hausmann MD hausmannMD
6 years 11 months ago
What unmet needs are found by young rheumatologists in Latin America? —>The opportunity to conduct research, especially money and time. Dr. Toro Gutierrez #ACR19 @RheumNow
Dr. Rachel Tate uptoTate
6 years 11 months ago
30-day rehospitalization after primary TKA or THA more likely in RA pts vs OA pts. All-type infections, AKI, and mechanical complications most common. https://t.co/iwPn9lCLrT #ACR19 @RheumNow abs#2872 https://t.co/hRUCXOysme
